1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

01 Aug 2024
Admin
News Article

Biogen, Beckman Coulter, and Fujirebio Team Up to Develop therapy for Alzheimer’s Disease

Biogen, Beckman Coulter, and Fujirebio Team Up to Develop Blood-Based Biomarkers and Tests for Tau Pathology in Alzheimer’s Disease

Overview

Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc., and Fujirebio have formed a collaboration to advance the development of blood-based biomarkers for tau pathology in Alzheimer's disease (AD). This partnership aims to create and improve tests that measure tau burden in the brain, providing valuable insights into AD's mechanisms and aiding the development of new therapies targeting tau pathology.

Aim for Collaboration

The collaboration will focus on both discovering novel blood-based biomarkers and refining existing ones for tau pathology in AD.
The objective is to develop diagnostic tools capable of measuring brain tau pathology, which could enhance patient stratification and treatment monitoring in clinical trials.
These tools may also be used in clinical practice, facilitating the adoption of future tau-targeting therapies.

Satement from Biogen

Biogen, remarked, “Improving patient stratification and monitoring for tau pathology is crucial for advancing Alzheimer’s therapies, including our investigational tau-targeting treatments. By leveraging our biomarker expertise alongside our partners’ diagnostic innovations, we aim to expedite the development of blood-based diagnostics for tau pathology.”

From Beckman Coulter Diagnostics

Kathleen Orland, Senior Vice President at Beckman Coulter Diagnostics, noted, “This collaboration merges cutting-edge biomarker development with promising tauopathy-focused treatments, advancing us toward effective solutions. Our goal is to make high-quality neurological tests widely available through our global network, improving access for patients with dementia.”

From Fujirebio Diagnostics

Fujirebio Diagnostics, added, “Blood-based biomarkers for tau pathology have the potential to significantly advance disease-modifying therapies for neurodegenerative disorders such as AD. This partnership will help us accelerate the development and global distribution of innovative diagnostics, addressing the pressing need for these biomarkers.”

Terms of Collaboration

Under the collaboration terms, Biogen will provide Alzheimer's clinical study data and expertise in biomarker research to help identify key tau pathology markers.
Fujirebio and Beckman Coulter will handle the development, manufacturing, and commercialization of the diagnostic tools.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!